Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk

By Mrinalika Roy and Mariam Sunny Aug 5 (Reuters) - Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and ...

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence ...
24/7 Wall St.

This Will be Eli Lilly’s Price in 2027 And Morgan Stanley Agrees

Eli Lilly just posted revenue growth near 50% and crushed earnings estimates, yet the stock barely moved. There is a specific ...

Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo

By Mrinalika Roy and Mariam Sunny Aug 5 (Reuters) - Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and ...
Fierce Pharma

Lilly's Zepbound remains physicians' favorite, even as oral obesity launches alter landscape

Injected weight loss drugs remain favored over newer oral treatments by a significant margin, with Eli Lilly’s Zepbound ...
24/7 Wall St.

GLP-1’s Drove Eli Lilly’s Record-Breaking Q2, but AI Will Be Its Future

Eli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may ...

Eli Lilly Q2 Earnings Review: Breath-Taking Results Mean Higher Ceiling On Stock Price Target

Eli Lilly and Company beats earnings, boosts 2026 guidance on GLP-1 drugs Mounjaro/Zepbound. Click here to read my most ...
Marketing Dive

Lilly’s women’s sports push gets assist from WNBA on Prime campaign

The pharmaceutical company partnered with Amazon Ads for a spot starring basketball legend and WNBA on Prime analyst Candace ...